Transmitted drug resistance in recently infected HIV-positive Individuals from four urban locations across Asia (2007-2010) - TASER-S

on behalf of the TREAT Asia Studies to Evaluate Resistance - Surveillance Study (TASER-S)

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The availability of HIV antiretroviral therapy (ART) has been associated with the development of transmitted drug resistance-associated mutations (TDRM). TDRM can compromise treatment effectiveness in patients initiating ART and the prevalence can vary in different clinical settings. In this study, we investigated the proportion of TDRM in treatment-naïve, recently infected HIV-positive individuals sampled from four urban locations across Asia between 2007-2010. Methods: Patients enrolled in the TREAT Asia Studies to Evaluate Resistance - Surveillance Study (TASER-S) were genotyped prior to ART initiation, with resulting resistance mutations analysed according to the WHO 2009 list. Results: Proportions of TDRM from recently infected individuals from TASER-S ranged from 0% to 8.7% - Hong Kong: 3/88 (3.4%, 95% CI (0.71%-9.64%)); Thailand: Bangkok: 13/277 (4.7%, 95% CI (2.5%-7.9%)), Chiang Mai: 0/17 (0%, 97.5% CI (0%-19.5%)); and the Philippines: 6/69 (8.7%, 95% CI (3.3%-18.0%)). There was no significant increase in TDRM over time across all four clinical settings. Conclusions: The observed proportion of TDRM in TASER-S patients from Hong Kong, Thailand and the Philippines was low to moderate during the study period. Regular monitoring of TDRM should be encouraged, especially with the scale-up of ART at higher CD4 levels.

Original languageEnglish
Article number3
JournalAIDS Research and Therapy
Volume12
Issue number1
DOIs
Publication statusPublished - Feb 13 2015
Externally publishedYes

Fingerprint

Drug Resistance
HIV
Mutation
Philippines
Hong Kong
Thailand
Therapeutics

Keywords

  • Asia
  • Drug resistance
  • Recent-infection
  • Resource-limited
  • Transmitted

ASJC Scopus subject areas

  • Molecular Medicine
  • Virology
  • Pharmacology (medical)

Cite this

Transmitted drug resistance in recently infected HIV-positive Individuals from four urban locations across Asia (2007-2010) - TASER-S. / on behalf of the TREAT Asia Studies to Evaluate Resistance - Surveillance Study (TASER-S).

In: AIDS Research and Therapy, Vol. 12, No. 1, 3, 13.02.2015.

Research output: Contribution to journalArticle

on behalf of the TREAT Asia Studies to Evaluate Resistance - Surveillance Study (TASER-S). / Transmitted drug resistance in recently infected HIV-positive Individuals from four urban locations across Asia (2007-2010) - TASER-S. In: AIDS Research and Therapy. 2015 ; Vol. 12, No. 1.
@article{610061bc7db14e6fbcb5ec5b17bb6440,
title = "Transmitted drug resistance in recently infected HIV-positive Individuals from four urban locations across Asia (2007-2010) - TASER-S",
abstract = "Background: The availability of HIV antiretroviral therapy (ART) has been associated with the development of transmitted drug resistance-associated mutations (TDRM). TDRM can compromise treatment effectiveness in patients initiating ART and the prevalence can vary in different clinical settings. In this study, we investigated the proportion of TDRM in treatment-na{\"i}ve, recently infected HIV-positive individuals sampled from four urban locations across Asia between 2007-2010. Methods: Patients enrolled in the TREAT Asia Studies to Evaluate Resistance - Surveillance Study (TASER-S) were genotyped prior to ART initiation, with resulting resistance mutations analysed according to the WHO 2009 list. Results: Proportions of TDRM from recently infected individuals from TASER-S ranged from 0{\%} to 8.7{\%} - Hong Kong: 3/88 (3.4{\%}, 95{\%} CI (0.71{\%}-9.64{\%})); Thailand: Bangkok: 13/277 (4.7{\%}, 95{\%} CI (2.5{\%}-7.9{\%})), Chiang Mai: 0/17 (0{\%}, 97.5{\%} CI (0{\%}-19.5{\%})); and the Philippines: 6/69 (8.7{\%}, 95{\%} CI (3.3{\%}-18.0{\%})). There was no significant increase in TDRM over time across all four clinical settings. Conclusions: The observed proportion of TDRM in TASER-S patients from Hong Kong, Thailand and the Philippines was low to moderate during the study period. Regular monitoring of TDRM should be encouraged, especially with the scale-up of ART at higher CD4 levels.",
keywords = "Asia, Drug resistance, Recent-infection, Resource-limited, Transmitted",
author = "{on behalf of the TREAT Asia Studies to Evaluate Resistance - Surveillance Study (TASER-S)} and Awachana Jiamsakul and Sunee Sirivichayakul and Rossana Ditangco and Wong, {Ka Hing} and Li, {Patrick C.K.} and Jutarat Praparattanapan and Praphan Phanuphak and Edelwisa Segubre-Mercado and Yam, {Wing Cheong} and Thira Sirisanthana and Thida Singtoroj and M. Law and Lee, {M. P.} and N. Kumarasamy and S. Saghayam and S. Pujari and K. Joshi and Merati, {T. P.} and F. Yuliana and Lee, {C. K.C.} and Sim, {B. L.H.} and A. Kamarulzaman and Ong, {L. Y.} and M. Mustafa and N. Nordin and Bantique, {R. O.} and Chen, {Y. M.A.} and Lin, {Y. T.} and S. Sungkanuparph and S. Kiertiburanakul and L. Chumla and P. Kantipong and P. Kambua and W. Ratanasuwan and R. Sriondee and R. Kantor and Sohn, {A. H.} and N. Durier and T. Singtoroj and Cooper, {D. A.} and M. Law and Boettiger, {D. C.}",
year = "2015",
month = "2",
day = "13",
doi = "10.1186/s12981-015-0043-1",
language = "English",
volume = "12",
journal = "AIDS Research and Therapy",
issn = "1742-6405",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Transmitted drug resistance in recently infected HIV-positive Individuals from four urban locations across Asia (2007-2010) - TASER-S

AU - on behalf of the TREAT Asia Studies to Evaluate Resistance - Surveillance Study (TASER-S)

AU - Jiamsakul, Awachana

AU - Sirivichayakul, Sunee

AU - Ditangco, Rossana

AU - Wong, Ka Hing

AU - Li, Patrick C.K.

AU - Praparattanapan, Jutarat

AU - Phanuphak, Praphan

AU - Segubre-Mercado, Edelwisa

AU - Yam, Wing Cheong

AU - Sirisanthana, Thira

AU - Singtoroj, Thida

AU - Law, M.

AU - Lee, M. P.

AU - Kumarasamy, N.

AU - Saghayam, S.

AU - Pujari, S.

AU - Joshi, K.

AU - Merati, T. P.

AU - Yuliana, F.

AU - Lee, C. K.C.

AU - Sim, B. L.H.

AU - Kamarulzaman, A.

AU - Ong, L. Y.

AU - Mustafa, M.

AU - Nordin, N.

AU - Bantique, R. O.

AU - Chen, Y. M.A.

AU - Lin, Y. T.

AU - Sungkanuparph, S.

AU - Kiertiburanakul, S.

AU - Chumla, L.

AU - Kantipong, P.

AU - Kambua, P.

AU - Ratanasuwan, W.

AU - Sriondee, R.

AU - Kantor, R.

AU - Sohn, A. H.

AU - Durier, N.

AU - Singtoroj, T.

AU - Cooper, D. A.

AU - Law, M.

AU - Boettiger, D. C.

PY - 2015/2/13

Y1 - 2015/2/13

N2 - Background: The availability of HIV antiretroviral therapy (ART) has been associated with the development of transmitted drug resistance-associated mutations (TDRM). TDRM can compromise treatment effectiveness in patients initiating ART and the prevalence can vary in different clinical settings. In this study, we investigated the proportion of TDRM in treatment-naïve, recently infected HIV-positive individuals sampled from four urban locations across Asia between 2007-2010. Methods: Patients enrolled in the TREAT Asia Studies to Evaluate Resistance - Surveillance Study (TASER-S) were genotyped prior to ART initiation, with resulting resistance mutations analysed according to the WHO 2009 list. Results: Proportions of TDRM from recently infected individuals from TASER-S ranged from 0% to 8.7% - Hong Kong: 3/88 (3.4%, 95% CI (0.71%-9.64%)); Thailand: Bangkok: 13/277 (4.7%, 95% CI (2.5%-7.9%)), Chiang Mai: 0/17 (0%, 97.5% CI (0%-19.5%)); and the Philippines: 6/69 (8.7%, 95% CI (3.3%-18.0%)). There was no significant increase in TDRM over time across all four clinical settings. Conclusions: The observed proportion of TDRM in TASER-S patients from Hong Kong, Thailand and the Philippines was low to moderate during the study period. Regular monitoring of TDRM should be encouraged, especially with the scale-up of ART at higher CD4 levels.

AB - Background: The availability of HIV antiretroviral therapy (ART) has been associated with the development of transmitted drug resistance-associated mutations (TDRM). TDRM can compromise treatment effectiveness in patients initiating ART and the prevalence can vary in different clinical settings. In this study, we investigated the proportion of TDRM in treatment-naïve, recently infected HIV-positive individuals sampled from four urban locations across Asia between 2007-2010. Methods: Patients enrolled in the TREAT Asia Studies to Evaluate Resistance - Surveillance Study (TASER-S) were genotyped prior to ART initiation, with resulting resistance mutations analysed according to the WHO 2009 list. Results: Proportions of TDRM from recently infected individuals from TASER-S ranged from 0% to 8.7% - Hong Kong: 3/88 (3.4%, 95% CI (0.71%-9.64%)); Thailand: Bangkok: 13/277 (4.7%, 95% CI (2.5%-7.9%)), Chiang Mai: 0/17 (0%, 97.5% CI (0%-19.5%)); and the Philippines: 6/69 (8.7%, 95% CI (3.3%-18.0%)). There was no significant increase in TDRM over time across all four clinical settings. Conclusions: The observed proportion of TDRM in TASER-S patients from Hong Kong, Thailand and the Philippines was low to moderate during the study period. Regular monitoring of TDRM should be encouraged, especially with the scale-up of ART at higher CD4 levels.

KW - Asia

KW - Drug resistance

KW - Recent-infection

KW - Resource-limited

KW - Transmitted

UR - http://www.scopus.com/inward/record.url?scp=84924274629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924274629&partnerID=8YFLogxK

U2 - 10.1186/s12981-015-0043-1

DO - 10.1186/s12981-015-0043-1

M3 - Article

VL - 12

JO - AIDS Research and Therapy

JF - AIDS Research and Therapy

SN - 1742-6405

IS - 1

M1 - 3

ER -